A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Trial Details

NCT ID
NCT07190248
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Calderasib
  • Pembrolizumab (+) Berahyaluronidase alfa
  • Pemetrexed
  • Cisplatin
  • Carboplatin
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Stamford, Connecticut, United States|41.05343,-73.53873
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • Lafayette, Indiana, United States|40.4167,-86.87529
  • Westbrook, Maine, United States|43.67703,-70.37116

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Has nonsquamous NSCLC (Stage IIIB, Stage IIIC) not eligible for curative resection or chemoradiation or Stage IV: M1a, M1b, or M1c
  • If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →